Показать сообщение отдельно
  #406  
Старый 24.09.2010, 19:59
Аватар для Chevychelov
Chevychelov Chevychelov вне форума ВРАЧ
Ветеран форума
      
 
Регистрация: 09.09.2006
Город: Тирасполь
Сообщений: 2,244
Сказал(а) спасибо: 73
Поблагодарили 163 раз(а) за 140 сообщений
Записей в дневнике: 54
Chevychelov этот участник имеет превосходную репутацию на форумеChevychelov этот участник имеет превосходную репутацию на форумеChevychelov этот участник имеет превосходную репутацию на форумеChevychelov этот участник имеет превосходную репутацию на форумеChevychelov этот участник имеет превосходную репутацию на форумеChevychelov этот участник имеет превосходную репутацию на форумеChevychelov этот участник имеет превосходную репутацию на форумеChevychelov этот участник имеет превосходную репутацию на форумеChevychelov этот участник имеет превосходную репутацию на форумеChevychelov этот участник имеет превосходную репутацию на форумеChevychelov этот участник имеет превосходную репутацию на форуме
Trial Summary
COMPARE
Title: Second-Generation Everolimus-Eluting and Paclitaxel-Eluting Stents in Real-Life Practice
Trial Sponsor: Abbott Vascular and Boston Scientific
Year Presented: 2009, 2010
Year Published: 2010
Topic(s): Interventional Cardiology
Summary Posted: 09/23/2010
Writer: Dharam J. Kumbhani, M.D., S.M.
Author Disclosure: NOTHING TO DISCLOSE
Reviewer: Deepak L. Bhatt, M.D., M.P.H., F.A.C.C.
Reviewer Disclosure: RESEARCH/RESEARCH GRANTS: Astra Zeneca, Heartscape, Eisai, Sanofi Aventis, The Medicines Company, Ethicon, Bristol Myers Squibb Cogentus, PLx Pharma, Takeda

Description:

The current trial sought to compare outcomes between the everolimus-eluting stent (EES) (Xience V) and paclitaxel-eluting stent (PES) (Taxus Liberte) in a real-world situation.
Hypothesis:
EES would be superior to PES in the treatment of coronary artery disease in unselected patients.
Drugs/Procedures Used:
Patients meeting enrollment criteria were randomized to receive either EES or PES in a 1:1 fashion.
Concomitant Medications:

Glycoprotein IIb/IIIa inhibitors (32%); aspirin 300 mg once, then 100 mg daily for life; clopidogrel 300 or 600 mg once, then 75 mg daily for 12 months
Principal Findings:

A total of 1,800 patients were randomized, 903 to PES and 897 to EES. Baseline characteristics were fairly similar between the two arms. About 25% of patients presented with acute myocardial infarction (MI), and 23% with non-ST-elevation MI. Multivessel disease was noted in 27% of the patients, and 18% were diabetic. Left main stenting was conducted in 2% of the patients. The mean stent length per lesion was 28 mm, and the mean number of lesions was 1.65 per patient.

The primary endpoint of major adverse cardiac events (MACE) at 1 year (all-cause mortality, nonfatal MI, and target vessel revascularization [TVR]) was significantly lower in the EES arm compared with PES (6.2% vs. 9.1%, hazard ratio [HR] 0.69, 95% confidence interval [CI] 0.50-0.95, p = 0.023). Similarly, the incidence of death, MI, and target lesion revascularization (TLR) at 1 year was significantly lower in the EES arm compared with PES (4.9% vs. 8.2%, HR 0.60, 95% CI 0.42-0.86, p = 0.005).

In addition, the incidence of nonfatal MI (2.8% vs. 5.4%, p = 0.007) and TVR (2.4% vs. 6.0%, p = 0.0001) was significantly lower in the EES arm. The incidence of stent thrombosis at 1 year was also significantly lower in the EES arm (0.7% vs. 2.6%, HR 0.26, 95% CI 0.11-0.64, p = 0.002). This was mainly due to a reduction in early stent thrombosis (p = 0.002), rather than late stent thrombosis (p = 0.25).

Two-year follow-up was available for 1,795 patients. Only 15.2% and 11.4% of patients were on dual antiplatelet therapy beyond 1 year of index procedure, respectively (p = 0.02). The primary endpoint of MACE at 2 years was still significantly lower in the EES arm compared with PES (9.0% vs. 13.7%, HR 0.66, 95% CI 0.50-0.86, p = 0.0016). The incidences of MI (3.9% vs. 7.6%, p = 0.0009) and stent thrombosis (0.9% vs. 3.9%, p < 0.0001) at 2 years were significantly lower in the EES arm (0.3% vs. 1.5%, p = 0.013), although only about 13% of the patients were on dual antiplatelet therapy beyond 1 year.
Interpretation:

The results of this trial indicate that EES is superior to PES (Taxus Liberte) in the reduction in clinical endpoints including MACE, nonfatal MI, and stent thrombosis at 1 year, when utilized in a real-world situation. These results are similar to those of the recently presented SPIRIT IV trial. Earlier studies had demonstrated a greater reduction in late lumen loss with EES. The current trial demonstrates that low late lumen loss can be achieved with EES without a concomitant increase in stent thrombosis, as compared with PES.

Two-year results show persistently better outcomes with EES compared with PES, including MACE, MI, and stent thrombosis. Beyond 1 year, when most patients were not on dual antiplatelet therapy, there was still a significant reduction in stent thrombosis with EES, as compared with PES. These findings are very important, and suggest that second-generation drug-eluting stents (DES) seem to have been successful in at least partially overcoming one of the biggest bete noire's of the first-generation stents: late stent thrombosis. Further long-term follow-up, and the performance of these second-generation DES, as compared with third-generation/bioabsorbable stents, is eagerly awaited.
Conditions:
Coronary heart disease
Therapies:
Stent/drug-eluting
Study Design:

Patients Enrolled: 1,800
Mean Follow Up: 1 year, then 2 years
Female: 30
Primary Endpoints:
All-cause mortality, nonfatal MI, and TVR at 1 year
Secondary Endpoints:
Cardiac death, nonfatal MI, and ischemia-driven TLR at 1 year, and then annually up to 5 years
All-cause mortality, nonfatal MI, and TVR at 2-5 years
Incidence of stent thrombosis annually during 5 years
Patient Population:
Patient is suitable candidate for PCI
Life expectancy >5 years
Exclusions:
No dual antiplatelet therapy for 1 year
Cardiogenic shock at presentation
Planned major surgery within 1 month
Participation in another trial
Ответить с цитированием